Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation.
Transplantation
; 86(1): 10-5, 2008 Jul 15.
Article
in En
| MEDLINE
| ID: mdl-18622269
ABSTRACT
Although clinical trials using anti-CD40L mAb have been halted, blockade of CD40-CD40L interactions has given promising results in rodent and nonhuman primate models. Recently, new insights into the consequences of blocking CD40-CD40L interactions have led to the possibility of overcoming the thromboembolic complications previously associated with this strategy and may pave the way for successful tolerance induction. This mini review will address the issues relating to CD40-CD40L blockade in allotransplantation.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Signal Transduction
/
Organ Transplantation
/
CD40 Antigens
/
CD40 Ligand
/
Transplantation Tolerance
/
Antibodies, Monoclonal
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Transplantation
Year:
2008
Type:
Article